Milde-Langosch K - Search Results

1

Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer.

Ihnen M, Wirtz RM, Kalogeras KT, Milde-Langosch K, Schmidt M, Witzel I, Eleftheraki AG, Papadimitriou C, Jänicke F, Briassoulis E, Pectasides D, Rody A, Fountzilas G, Müller V. Ihnen M, et al. Br J Cancer. 2010 Sep 28;103(7):1048-56. doi: 10.1038/sj.bjc.6605840. Epub 2010 Aug 24. Br J Cancer. 2010. PMID: 20736952 Free PMC article.

2

Expression of Rb2/p130 in breast and endometrial cancer: correlations with hormone receptor status.

Milde-Langosch K, Goemann C, Methner C, Rieck G, Bamberger AM, Löning T. Milde-Langosch K, et al. Br J Cancer. 2001 Aug 17;85(4):546-51. doi: 10.1054/bjoc.2001.1923. Br J Cancer. 2001. PMID: 11506494 Free PMC article.

3

Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype.

Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Löning T. Milde-Langosch K, et al. Breast Cancer Res Treat. 2001 May;67(1):61-70. doi: 10.1023/a:1010623308275. Breast Cancer Res Treat. 2001. PMID: 11518467

4

FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas.

Milde-Langosch K, Kappes H, Riethdorf S, Löning T, Bamberger AM. Milde-Langosch K, et al. Breast Cancer Res Treat. 2003 Feb;77(3):265-75. doi: 10.1023/a:1021887100216. Breast Cancer Res Treat. 2003. PMID: 12602926

5

Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer.

Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, Müller V, Löning T. Milde-Langosch K, et al. Br J Cancer. 2005 Jun 20;92(12):2206-15. doi: 10.1038/sj.bjc.6602655. Br J Cancer. 2005. PMID: 15928662 Free PMC article.

6

Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.

Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, Löning T. Kröger N, et al. Clin Cancer Res. 2006 Jan 1;12(1):159-68. doi: 10.1158/1078-0432.CCR-05-1340. Clin Cancer Res. 2006. PMID: 16397038

7

Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility.

Milde-Langosch K, Janke S, Wagner I, Schröder C, Streichert T, Bamberger AM, Jänicke F, Löning T. Milde-Langosch K, et al. Breast Cancer Res Treat. 2008 Feb;107(3):337-47. doi: 10.1007/s10549-007-9559-y. Epub 2007 Mar 28. Breast Cancer Res Treat. 2008. PMID: 17393299

8

Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer.

Ihnen M, Müller V, Wirtz RM, Schröder C, Krenkel S, Witzel I, Lisboa BW, Jänicke F, Milde-Langosch K. Ihnen M, et al. Breast Cancer Res Treat. 2008 Dec;112(3):419-27. doi: 10.1007/s10549-007-9879-y. Epub 2008 Jan 3. Breast Cancer Res Treat. 2008. PMID: 18172759

9

Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.

Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Barrels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, Niendorf A, Kröger N, Wenzel S, Leuwer R, Bokemeyer C, Hegewisch-Becker S, Atanackovic D. Panse J, et al. Br J Cancer. 2008 Sep 16;99(6):930-8. doi: 10.1038/sj.bjc.6604621. Br J Cancer. 2008. PMID: 18781150 Free PMC article.

10

[Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy].

Kilic E, Milde-Langosch K, Müller V, Wirtz R, Ihnen M. Kilic E, et al. Pathologe. 2008 Nov;29 Suppl 2:347-52. doi: 10.1007/s00292-008-1080-5. Pathologe. 2008. PMID: 18810438 German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

128 results

Search Page

Filters